Cargando…

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach

Significant reductions in the incidence of cardiac arrhythmia (CA) and sudden cardiac death (SCD), along with amelioration of heart failure, have been reported for treatment with Sacubitril/valsartan (SV). However, its anti-arrhythmic mechanism remains unclear. The current study aims to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu, Rui, Shibao, Tang, Shengxin, Ju, Changlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043521/ https://www.ncbi.nlm.nih.gov/pubmed/35498046 http://dx.doi.org/10.3389/fcvm.2022.829484

Ejemplares similares

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
por: Liu, Xue-Hui, et al.
Publicado: (2022)

Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Ruxin, et al.
Publicado: (2022)

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
por: Yang, Pei, et al.
Publicado: (2023)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
por: Guo, Yanhong, et al.
Publicado: (2022)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
por: Litwin, Sheldon E., et al.
Publicado: (2022)

Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: A randomized clinical trial
por: Lyu, Tian-Jiao, et al.
Publicado: (2022)

Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
por: Monosilio, Sara, et al.
Publicado: (2022)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
por: Chen, Qingsong, et al.
Publicado: (2022)

Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan
por: Hsu, Chien-Yi, et al.
Publicado: (2022)

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
por: Lee, Vivian, et al.
Publicado: (2023)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Pascual-Figal, Domingo, et al.
Publicado: (2021)

Reduction of Pulmonary Hypertension After Transition to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction
por: Burgdorf, Christof, et al.
Publicado: (2021)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Yu, Wanqian, et al.
Publicado: (2022)

Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later
por: Tao, Wenqi, et al.
Publicado: (2023)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
por: Pathadka, Swathi, et al.
Publicado: (2021)

Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea
por: Pelaia, Corrado, et al.
Publicado: (2022)

Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials
por: Song, Yinyin, et al.
Publicado: (2022)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Sacubitril/Valsartan: Potential Impact of ARNi “Beyond the Wall” of ACE2 on Treatment and Prognosis of Heart Failure Patients With Coronavirus Disease-19
por: Rubattu, Speranza, et al.
Publicado: (2020)

Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
por: Mapelli, Massimo, et al.
Publicado: (2022)

A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction
por: Zhou, Xiaomin, et al.
Publicado: (2022)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Predictors of permanent pacemaker implantation in aortic valve diseases after TAVI with vitaFlow liberty system
por: Ju, Changlin, et al.
Publicado: (2023)

Transfer RNA-derived small RNAs and their potential roles in the therapeutic heterogeneity of sacubitril/valsartan in heart failure patients after acute myocardial infarction
por: Su, Jia, et al.
Publicado: (2022)

Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis
por: Zhang, Dong, et al.
Publicado: (2022)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
por: Iborra-Egea, Oriol, et al.
Publicado: (2017)

Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
por: Seferovic, Jelena P., et al.
Publicado: (2020)

Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology
por: Canale, Maria Laura, et al.
Publicado: (2022)

Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
por: Vitiello, Antonio, et al.
Publicado: (2021)

Effects of Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction in Patients Undergoing Peritoneal Dialysis
por: Fu, Sha, et al.
Publicado: (2021)

Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients
por: El-Battrawy, Ibrahim, et al.
Publicado: (2019)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_60m95k9b8j7a3sfjlh52it9sht